Table 5.

Summary of reported patients who exhibited thyroiditis and isolated adrenocorticotropic hormone deficiency in association with cancer treatment with nivolumab

Ref.	Age/sex	Nivolumab			Thyroiditis				IAD				Other IRAEs
		Target cancer	Regimen	Administration times (courses)	Time from first nivolumab administration to thyroiditis onset (months)	Thyroid function abnormality	Thyroid autoantibodies	Abnormality on thyroid ultrasonography	Time from first nivolumab administration to IAD onset (months)	Major symptoms	Pituitary autoantibodies	Morphological abnormality in the pituitary on MRI
[15]	60/M	LAC	3 mg/kg every 2 weeks	11	5	Hypothyroidism	N/D	N/D	7	Fatigue, anorexia, dizziness, gait instability	N/D	None	None
[16]	54/M	RCC	2 mg/kg every 2 weeks	12	3	Hypothyroidism	Positive (TgAb and TPOAb)	N/D	6	Fatigue, hypoglycemia	N/D	None	None
[19]	58/M	Melanoma	3 mg/kg every 2 weeks	N/D	4	Transient thyrotoxicosis and subsequent hypothyroidism	Positive (TgAb)	N/D	8	Fatigue, anorexia, weakness	N/D	None	Hypercalcemia
[20]	63/F	Melanoma	2 mg/kg every 3 weeks	8	6	Transient thyrotoxicosis and subsequent hypothyroidism	Positive (TgAb)	Low echogenicity	8	Fatigue	N/D	None	None
Present case	69/F	LAC	3 mg/kg every 2 weeks	6	2	Transient thyrotoxicosis and subsequent hypothyroidism	Negative	Low echogenicity	7	Fatigue, anorexia, weakness	Negative	Atrophy	None

F female, IAD isolated adrenocorticotropic hormone deficiency, IRAE immune-related adverse event, LAC lung adenocarcinoma, M male, MRI magnetic resonance imaging, N/D not described, RCC renal cell carcinoma, TgAb thyroglobulin autoantibody, TPOAb thyroid peroxidase autoantibody